David Lamond - 02 Jan 2026 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role: Director
Signature: /s/ Brendan Hannah as attorney-in-fact for David Lamond
Issuer symbol: QNCX
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 21 Jan 2026, 18:05:21 UTC
Previous filing: 06 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lamond David	Director	C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO	/s/ Brendan Hannah as attorney-in-fact for David Lamond	21 Jan 2026	0001770790

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QNCX	Director Stock Option (Right to Buy)	Award	$0	+29,423		$0.000000	29,423	02 Jan 2026	Common Stock	29,423	$3.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.